特一药业集团股份有限公司关于股份回购实施完成暨股份变动的公告

Core Viewpoint - The company has successfully completed its share repurchase program, acquiring a total of 13,729,618 shares, which represents 2.68% of its total share capital, within the stipulated timeframe and budget [2][3][4]. Group 1: Share Repurchase Implementation - The company initiated the share repurchase on June 24, 2024, purchasing 258,000 shares at a price range of 7.88 to 7.91 RMB per share, totaling approximately 2.04 million RMB [2]. - By June 10, 2025, the company had repurchased a total of 13,729,618 shares, with a maximum price of 8.03 RMB and a minimum price of 6.79 RMB per share, amounting to approximately 101.19 million RMB [3]. - The actual implementation of the share repurchase aligns with the previously approved plan, meeting the lower limit of the budget without exceeding the upper limit [4]. Group 2: Impact of Share Repurchase - The share repurchase is not expected to significantly impact the company's operations, finances, research and development, debt obligations, or future growth, nor will it alter the company's control or listing status [5]. - The total share capital remains unchanged, and the repurchased shares are intended for future employee stock ownership plans or equity incentives [8]. Group 3: Compliance and Future Arrangements - The company has adhered to all relevant regulations regarding the timing, quantity, and pricing of the share repurchase, ensuring compliance with the rules set by the Shenzhen Stock Exchange and the China Securities Regulatory Commission [7]. - The repurchased shares will be held in a dedicated account and will not confer any shareholder rights during the holding period. If not utilized within three years, the shares will be canceled [9].